NASDAQ:ICPT

Intercept Pharmaceuticals Stock Forecast, Price & News

$19.81
-0.43 (-2.12 %)
(As of 06/18/2021 12:00 AM ET)
Add
Compare
Today's Range
$19.45
$20.18
50-Day Range
$15.46
$22.14
52-Week Range
$13.88
$83.57
Volume1.10 million shs
Average Volume1.11 million shs
Market Capitalization$656.94 million
P/E RatioN/A
Dividend YieldN/A
Beta1.54
30 days | 90 days | 365 days | Advanced Chart
Receive ICPT News and Ratings via Email

Sign-up to receive the latest news and ratings for Intercept Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Intercept Pharmaceuticals logo

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. Its lead products candidate is the Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults. The company is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis (NASH); and other product candidates in various stages of clinical and preclinical development. It has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. The company markets its products through an internal commercial organization, a contract sales organization, and third-party distributors. Intercept Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in New York, New York.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.90 out of 5 stars

Medical Sector

130th out of 2,097 stocks

Pharmaceutical Preparations Industry

56th out of 831 stocks

Analyst Opinion: 4.1Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Intercept Pharmaceuticals (NASDAQ:ICPT) Frequently Asked Questions

Is Intercept Pharmaceuticals a buy right now?

24 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intercept Pharmaceuticals in the last year. There are currently 1 sell rating, 16 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Intercept Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ICPT, but not buy additional shares or sell existing shares.
View analyst ratings for Intercept Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Intercept Pharmaceuticals?

Wall Street analysts have given Intercept Pharmaceuticals a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Intercept Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Intercept Pharmaceuticals' next earnings date?

Intercept Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Intercept Pharmaceuticals
.

How were Intercept Pharmaceuticals' earnings last quarter?

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) released its earnings results on Thursday, May, 6th. The biopharmaceutical company reported ($1.22) earnings per share for the quarter, beating the consensus estimate of ($1.53) by $0.31. The biopharmaceutical company earned $81.66 million during the quarter, compared to analysts' expectations of $81.17 million. The business's revenue for the quarter was up 12.4% on a year-over-year basis. During the same period in the previous year, the business earned ($2.86) earnings per share.
View Intercept Pharmaceuticals' earnings history
.

How has Intercept Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

Intercept Pharmaceuticals' stock was trading at $77.60 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ICPT shares have decreased by 74.5% and is now trading at $19.81.
View which stocks have been most impacted by COVID-19
.

What guidance has Intercept Pharmaceuticals issued on next quarter's earnings?

Intercept Pharmaceuticals issued an update on its FY 2021 earnings guidance on Thursday, May, 27th. The company provided earnings per share (EPS) guidance of - for the period. The company issued revenue guidance of $325 million-$340 million, compared to the consensus revenue estimate of $341.54 million.

What price target have analysts set for ICPT?

24 brokerages have issued 1 year price objectives for Intercept Pharmaceuticals' shares. Their forecasts range from $16.00 to $88.00. On average, they anticipate Intercept Pharmaceuticals' stock price to reach $40.78 in the next twelve months. This suggests a possible upside of 105.9% from the stock's current price.
View analysts' price targets for Intercept Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Intercept Pharmaceuticals' key executives?

Intercept Pharmaceuticals' management team includes the following people:
  • Mr. Jerome B. Durso, Pres & CEO (Age 53, Pay $853.17k)
  • Dr. Mark Pruzanski, Founder, Advisor & Director (Age 53, Pay $1.3M)
  • Dr. Christian Weyer, Exec. VP of R&D (Age 51, Pay $679.45k)
  • Mr. Rocco Venezia, Chief Accounting Officer, Treasurer & Acting CFO
  • Ms. Lisa M. DeFrancesco, Sr. VP of Corp. Affairs & Investor Relations (Age 42)
  • Mr. Jared M. Freedberg, Gen. Counsel & Sec. (Age 52)
  • Mr. David Ford, Chief HR Officer (Age 51)
  • Dr. Gail Cawkwell, Sr. VP of Medical Affairs, Safety & Pharmacovigilance and Acting Chief Medical Officer (Age 58)
  • Ms. Linda M. Richardson, Exec. VP & Chief Commercial Officer (Age 57)
  • Mr. Bryan Ball, Chief Quality Officer (Age 51)

What is Mark Pruzanski's approval rating as Intercept Pharmaceuticals' CEO?

32 employees have rated Intercept Pharmaceuticals CEO Mark Pruzanski on Glassdoor.com. Mark Pruzanski has an approval rating of 80% among Intercept Pharmaceuticals' employees.

Who are some of Intercept Pharmaceuticals' key competitors?

What other stocks do shareholders of Intercept Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intercept Pharmaceuticals investors own include Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), Tesla (TSLA), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Micron Technology (MU), Ionis Pharmaceuticals (IONS), Regeneron Pharmaceuticals (REGN) and Biogen (biib).

What is Intercept Pharmaceuticals' stock symbol?

Intercept Pharmaceuticals trades on the NASDAQ under the ticker symbol "ICPT."

Who are Intercept Pharmaceuticals' major shareholders?

Intercept Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Samsara BioCapital LLC (1.93%), Goldman Sachs Group Inc. (1.50%), Geode Capital Management LLC (1.39%), Voloridge Investment Management LLC (1.09%), Northern Trust Corp (0.86%) and Altrinsic Global Advisors LLC (0.51%). Company insiders that own Intercept Pharmaceuticals stock include Christian Weyer, David A Ford, Gail Cawkwell, Jason Campagna, Lisa Bright, Mark Pruzanski, Paolo Fundaro, Ryan T Sullivan, Sandip Kapadia, SPA Genextra and Srinivas Akkaraju.
View institutional ownership trends for Intercept Pharmaceuticals
.

Which institutional investors are selling Intercept Pharmaceuticals stock?

ICPT stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Renaissance Technologies LLC, Altrinsic Global Advisors LLC, Millennium Management LLC, Russell Investments Group Ltd., Cubist Systematic Strategies LLC, Duality Advisers LP, and Pinnacle Associates Ltd.. Company insiders that have sold Intercept Pharmaceuticals company stock in the last year include Jason Campagna, Paolo Fundaro, Sandip Kapadia, and SPA Genextra.
View insider buying and selling activity for Intercept Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Intercept Pharmaceuticals stock?

ICPT stock was bought by a variety of institutional investors in the last quarter, including Samsara BioCapital LLC, Hennion & Walsh Asset Management Inc., Rafferty Asset Management LLC, Squarepoint Ops LLC, Geode Capital Management LLC, Capital Fund Management S.A., Trexquant Investment LP, and Gabelli Funds LLC.
View insider buying and selling activity for Intercept Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Intercept Pharmaceuticals?

Shares of ICPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Intercept Pharmaceuticals' stock price today?

One share of ICPT stock can currently be purchased for approximately $19.81.

How much money does Intercept Pharmaceuticals make?

Intercept Pharmaceuticals has a market capitalization of $656.94 million and generates $312.69 million in revenue each year. The biopharmaceutical company earns $-274,880,000.00 in net income (profit) each year or ($8.34) on an earnings per share basis.

How many employees does Intercept Pharmaceuticals have?

Intercept Pharmaceuticals employs 498 workers across the globe.

What is Intercept Pharmaceuticals' official website?

The official website for Intercept Pharmaceuticals is www.interceptpharma.com.

Where are Intercept Pharmaceuticals' headquarters?

Intercept Pharmaceuticals is headquartered at 10 Hudson Yards 37th FL, New York NY, 10001.

How can I contact Intercept Pharmaceuticals?

Intercept Pharmaceuticals' mailing address is 10 Hudson Yards 37th FL, New York NY, 10001. The biopharmaceutical company can be reached via phone at 646-747-1000 or via email at [email protected]


This page was last updated on 6/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.